BR0114846A - Método para produzir cristais de tipo b de nateglinida substancialmente livres de cristais de tipo h - Google Patents

Método para produzir cristais de tipo b de nateglinida substancialmente livres de cristais de tipo h

Info

Publication number
BR0114846A
BR0114846A BR0114846-0A BR0114846A BR0114846A BR 0114846 A BR0114846 A BR 0114846A BR 0114846 A BR0114846 A BR 0114846A BR 0114846 A BR0114846 A BR 0114846A
Authority
BR
Brazil
Prior art keywords
crystals
type
nateglinide
substantially free
producing nateglinide
Prior art date
Application number
BR0114846-0A
Other languages
English (en)
Inventor
Michito Sumikawa
Makoto Maruo
Kazuo Miyazaki
Shigehiro Nishina
Yukiko Matsuzawa
Original Assignee
Ajinomoto Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Kk filed Critical Ajinomoto Kk
Publication of BR0114846A publication Critical patent/BR0114846A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/38—Separation; Purification; Stabilisation; Use of additives
    • C07C227/40—Separation; Purification
    • C07C227/42—Crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"MéTODO PARA PRODUZIR CRISTAIS DE TIPO B DE NATEGLINIDA SUBSTANCIALMENTE LIVRES DE CRISTAIS DE TIPO H". é proporcionado um método para produzir cristais de tipo B de nateglinida substancialmente livres de cristais de tipo H, o qual compreende as etapas de: secar cristais úmidos solvatados de nateglinida em uma temperatura baixa até que não reste qualquer solvente e realizar uma conversão de cristais dos mesmos. De acordo com este método, os cristais de tipo B de nateglinida podem ser produzidos em uma escala industrial sem permitir que coexistam outras formas de polimorfismo cristalino.
BR0114846-0A 2000-10-24 2001-10-23 Método para produzir cristais de tipo b de nateglinida substancialmente livres de cristais de tipo h BR0114846A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000324375 2000-10-24
PCT/JP2001/009293 WO2002034713A1 (fr) 2000-10-24 2001-10-23 Procede de production de cristaux de nateglinide a forme b

Publications (1)

Publication Number Publication Date
BR0114846A true BR0114846A (pt) 2004-02-25

Family

ID=18801920

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0114846-0A BR0114846A (pt) 2000-10-24 2001-10-23 Método para produzir cristais de tipo b de nateglinida substancialmente livres de cristais de tipo h

Country Status (18)

Country Link
US (2) US20030229249A1 (pt)
EP (1) EP1334964B1 (pt)
JP (1) JP4225057B2 (pt)
KR (1) KR100810930B1 (pt)
CN (1) CN100422143C (pt)
AT (1) ATE370115T1 (pt)
AU (1) AU2001296001A1 (pt)
BR (1) BR0114846A (pt)
CA (1) CA2426745C (pt)
CY (1) CY1106839T1 (pt)
DE (1) DE60130014T2 (pt)
DK (1) DK1334964T3 (pt)
ES (1) ES2288997T3 (pt)
MX (1) MXPA03003575A (pt)
PT (1) PT1334964E (pt)
RU (1) RU2275354C2 (pt)
TW (1) TWI293290B (pt)
WO (1) WO2002034713A1 (pt)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02009130A (es) * 2000-03-17 2003-03-12 Ajinomoto Kk Farmacos para complicaciones de diabetes y neuropatia y utilizacion de los mismos.
WO2002032853A1 (fr) * 2000-10-18 2002-04-25 Ajinomoto Co.,Inc. Procede de preparation d'acylphenylalanines
CN100384814C (zh) * 2000-10-18 2008-04-30 味之素株式会社 那格列胺结晶的制备方法
ATE406885T1 (de) * 2000-10-24 2008-09-15 Ajinomoto Kk Nateglinid enthaltende präparate
EP1334721B1 (en) * 2000-10-24 2009-04-22 Ajinomoto Co., Inc. Nateglinide-containing hydrophilic drug preparations
AU2003236243A1 (en) * 2002-04-15 2003-10-27 Ajinomoto Co., Inc. Novel nateglinide crystal
US7411089B2 (en) 2002-04-15 2008-08-12 Ajinomoto Co., Inc. Nateglinide crystals
US6861553B2 (en) 2002-07-03 2005-03-01 Teva Pharmaceuticals Industries Ltd. Process for preparing nateglinide and intermediates thereof
JP2006511614A (ja) * 2002-07-18 2006-04-06 テバ ファーマシューティカル インダストリーズ リミティド ナテグリニドの多形性形状
US7534913B2 (en) 2002-07-18 2009-05-19 Teva Pharmaceutica Industries Ltd. Crystalline form of nateglinide
US7420084B2 (en) 2002-07-18 2008-09-02 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7148376B2 (en) 2002-07-18 2006-12-12 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7358390B2 (en) 2002-07-18 2008-04-15 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
ATE349418T1 (de) * 2003-11-26 2007-01-15 A M S A Anonima Materie Sint E Verfahren zur herstellung von nateglinidin der b- form
US20060004102A1 (en) * 2004-05-07 2006-01-05 Shlomit Wizel Polymorphic forms of nateglinide
WO2005110395A1 (en) * 2004-05-19 2005-11-24 University Of South Carolina System and device for magnetic drug targeting with magnetic drug carrier particles
WO2005113485A2 (en) * 2004-05-20 2005-12-01 Dr. Reddy's Laboratories Ltd. Stable nateglinide form b compositions
US7425648B2 (en) 2005-01-03 2008-09-16 A.M.S.A. Anonima Materie Sintetiche E. Affini S.P.A. Process for the preparation of nateglinide, preferably in B-form
EP1891971A4 (en) * 2005-01-31 2010-02-03 Ajinomoto Kk MEDICAL COMPOSITION USING HYPERGLY CRAB MEDICAMENT TO TREAT OR TREAT GLUCOSE-INTOLERANCE, BORDERLINE DIABETES, INSULIN RESISTANCE AND HYPERINSULINEMIA
WO2007135533A1 (en) * 2006-05-23 2007-11-29 Aurobindo Pharma Limited Process for preparing nateglinide b-type crystals
KR100837843B1 (ko) * 2006-12-26 2008-06-13 씨제이제일제당 (주) 나테글리나이드 결정형, 그 제조방법, 및 그를 포함하는약제학적 조성물
US9150499B2 (en) 2010-06-14 2015-10-06 Cipla Limited Process for the preparation of nateglinide
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
WO2013168021A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
JP2015519333A (ja) 2012-05-07 2015-07-09 セリックスビオ プライヴェート リミテッド 神経疾患の治療のための組成物および方法
WO2013167990A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of depression
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
US9309233B2 (en) 2012-05-08 2016-04-12 Cellix Bio Private Limited Compositions and methods for the treatment of blood clotting disorders
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
WO2013167987A1 (en) * 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of diabetes
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
WO2013167993A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological degenerative disorders
SG11201407318UA (en) 2012-05-10 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of metabolic syndrome
US9315461B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013168012A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
WO2013168011A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of chronic pain
WO2013168001A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
US9394288B2 (en) 2012-05-10 2016-07-19 Cellix Bio Private Limited Compositions and methods for the treatment of asthma and allergy
US9315478B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
WO2013168014A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of familial amyloid polyneuropathy
WO2013168033A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
CA2873096A1 (en) 2012-05-23 2013-11-28 Cellixbio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
EP2852569B1 (en) 2012-05-23 2020-10-14 Cellixbio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9434729B2 (en) 2012-05-23 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
CA2873104A1 (en) 2012-05-23 2013-11-28 Cellixbio Private Limited Compositions and methods for the treatment of mucositis
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9187427B2 (en) 2012-08-03 2015-11-17 Cellix Bio Private Limited N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
US9670153B2 (en) 2012-09-08 2017-06-06 Cellix Bio Private Limited Compositions and methods for the treatment of inflammation and lipid disorders
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
CA2914461A1 (en) 2013-06-04 2014-12-11 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
SG11201706952VA (en) 2014-09-26 2017-10-30 Cellix Bio Private Ltd Compositions and methods for the treatment of epilepsy and neurological disorders
CA2967908C (en) 2014-09-29 2020-11-17 Mahesh Kandula Compositions and methods for the treatment of multiple sclerosis
JP6564868B2 (ja) 2014-10-27 2019-08-21 セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ 多発性硬化症の治療のための、フマル酸モノメチルエステルとピペラジン又はエチレンジアミンとの３つの成分の塩
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
CN104402756B (zh) * 2014-11-27 2016-08-31 天方药业有限公司 一种高纯度那格列奈的制备方法
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
CA2973178C (en) 2015-01-06 2022-11-01 Cellix Bio Private Limited Bupivacaine derivatives and their use in the treatment of inflammation and pain
CN109369443A (zh) * 2018-11-05 2019-02-22 扬子江药业集团江苏海慈生物药业有限公司 一种新的那格列奈h晶型的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6354321A (ja) * 1985-03-27 1988-03-08 Ajinomoto Co Inc 血糖降下剤
JP2508949B2 (ja) * 1991-07-30 1996-06-19 味の素株式会社 Ｎ−（トランス−４−イソプロピルシクロヘキシルカルボニル）−ｄ−フェニルアラニンの結晶及びその製造法
US5463116A (en) 1991-07-30 1995-10-31 Ajinomoto Co., Inc. Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them
DE69735644T2 (de) * 1996-11-15 2007-05-03 Ajinomoto Co., Inc. Nateglinide zubereitung in tablettenform
US6844006B1 (en) * 1999-07-09 2005-01-18 Pennfield Oil Company Process and apparatus for the preparation of chlortetracycline-containing animal feed compositions
ATE399000T1 (de) * 1999-12-28 2008-07-15 Ajinomoto Kk Antidiabetes-zubereitung zur oralen verabreichung
MXPA02009130A (es) * 2000-03-17 2003-03-12 Ajinomoto Kk Farmacos para complicaciones de diabetes y neuropatia y utilizacion de los mismos.
CN100384814C (zh) * 2000-10-18 2008-04-30 味之素株式会社 那格列胺结晶的制备方法
WO2002032853A1 (fr) * 2000-10-18 2002-04-25 Ajinomoto Co.,Inc. Procede de preparation d'acylphenylalanines
ATE406885T1 (de) * 2000-10-24 2008-09-15 Ajinomoto Kk Nateglinid enthaltende präparate
US7411089B2 (en) * 2002-04-15 2008-08-12 Ajinomoto Co., Inc. Nateglinide crystals

Also Published As

Publication number Publication date
EP1334964B1 (en) 2007-08-15
KR100810930B1 (ko) 2008-03-10
TWI293290B (pt) 2008-02-11
ATE370115T1 (de) 2007-09-15
DK1334964T3 (da) 2007-09-24
JP4225057B2 (ja) 2009-02-18
EP1334964A4 (en) 2005-09-28
PT1334964E (pt) 2007-09-20
ES2288997T3 (es) 2008-02-01
AU2001296001A1 (en) 2002-05-06
RU2275354C2 (ru) 2006-04-27
WO2002034713A1 (fr) 2002-05-02
DE60130014T2 (de) 2008-05-08
MXPA03003575A (es) 2003-07-14
US20030229249A1 (en) 2003-12-11
CN100422143C (zh) 2008-10-01
CN1483018A (zh) 2004-03-17
US7544834B2 (en) 2009-06-09
EP1334964A1 (en) 2003-08-13
CA2426745A1 (en) 2003-04-23
CY1106839T1 (el) 2012-05-23
US20070232829A1 (en) 2007-10-04
DE60130014D1 (de) 2007-09-27
KR20030059212A (ko) 2003-07-07
JPWO2002034713A1 (ja) 2004-03-04
CA2426745C (en) 2009-09-15

Similar Documents

Publication Publication Date Title
BR0114846A (pt) Método para produzir cristais de tipo b de nateglinida substancialmente livres de cristais de tipo h
BR0008050A (pt) Processo e dispositivo para filtração emcontracorrente
BR0209246A (pt) Resolução de sal quiral
BR0008236A (pt) Processo de remoção de biofilmes das superfìciessubmersas em um sistema de águas impuras
DE69921350D1 (de) Nicht-korrodierende entfernungs-und reinigungs-zusammensetzung
RU2003111948A (ru) Способы получения кристаллов в-типа натеглинида
PT1144368E (pt) Sulfonamidas acetilenicas de acidos hidroxamicos baseados em alfa-aminoacidos como inibidores de tace
BR0308385B1 (pt) processo para purificar uma composição compreendendo ácido (met)acrílico, aparelho para produzir ácido (met)acrílico e aparelho para polimerizar ácido (met)acrílico
BR0005488A (pt) Processo para a preparação de carbonato de vinileno, e o uso do mesmo
BR0310005A (pt) Método para a produção de ácido orgânico
BR0303196A (pt) Suporte de montagem de uma extremidade frontal de um veìculo automotor e processo para a fixação destacável de um módulo de refrigeração em um suporte de montagem de uma extremidade frontal
BR9604801A (pt) Processo para a produção e purificação de esteres cìclicos
BRPI0400375A (pt) Processo para remover vìrus em soluções de fibrinogênio para aplicação terapêutica e fibrinogênio obtido pelo dito processo
BR9712305A (pt) Processo para concentrar ácidos sulf·ricos desperdiçados
DE50101929D1 (de) Dermales applikationssystem für aminolävulinsäure
BR0108912A (pt) Processamento de material por expansão-contração de solvente repetido
BRPI0212411B8 (pt) ' processos para reduzir os níveis de solventes orgânicos em um sólido de carbapenem, e para fabricar um hidrato cristalino'
BR0312604A (pt) ácidos imido-alcanpercarboxìlicos, composições, e, processo para a preparação e uso de ácidos imido-alcanpercarboxìlicos
BR9711971A (pt) Processo para a produ-Æo de difluometano
BRPI0414877A (pt) processo e dispositivo para alterar o comportamento de vibraçao de um sistema de motor
SE7808864L (sv) Sett att nyttiggora det huvudsakligen som biprodukt vid kommunal avloppsvattenrening bildade slammet innehallande organiska fororeningar, jemte anleggning for settets genomforande
DE60137686D1 (de) Verfahren zur kristallisation von n-(1(s)-ethoxycarbonyl-3-phenylpropyl)-l-alanin n-carbonsäureanhydrid
BR0205164A (pt) Processo para purificar azeotropicamente material orgânico polimerizável aquoso
BR0307300A (pt) Integração de pelo menos dois processos para reutilizar ácido
BR0214531A (pt) Processo para reduzir a toxidade de pelo menos um Ènio-composto em uma solução aquosa, e respectiva solução aquosa

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: PAGAR RESTAURACAO.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 NA RPI 2274 DE 05/08/2014

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2308 DE 31/03/2015.